CervoMed Inc. (CRVO)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Grant revenue | 1,757,724 | 1,917,491 | 1,939,751 | 3,288,971 |
| Research and development | 5,108,625 | 4,837,798 | 5,125,097 | 3,772,391 |
| General and administrative | 3,265,374 | 2,382,577 | 2,210,927 | 2,511,679 |
| Total operating expenses | 8,373,999 | 7,220,375 | 7,336,024 | 6,284,070 |
| Loss from operations | -6,616,275 | -5,302,884 | -5,396,273 | -2,995,099 |
| Other expense | -10,256 | -135 | -3,440 | -247 |
| Interest income | 368,127 | 408,985 | 646,172 | 678,441 |
| Total other income, net | 357,871 | 408,850 | 642,732 | 678,194 |
| Net loss | -6,258,404 | -4,894,034 | -4,753,541 | -2,316,905 |
| Net unrealized loss on marketable securities | -22,006 | -34,974 | 142,864 | -19,702 |
| Total comprehensive loss | -6,280,410 | -4,929,008 | -4,610,677 | -2,336,607 |
| Diluted eps | - | - | -0.55 | - |
| Diluted average shares | - | - | 8,702,764 | - |
| Net loss per share of common stock, basic and diluted (in dollars per share) | -0.7 | -0.56 | -0.55 | -0.27 |
| Weighted average shares outstanding, basic and diluted (in shares) | 8,950,521 | 8,702,719 | 8,702,764 | 8,702,764 |